Chemistry:Setidegrasib
From HandWiki
Setidegrasib is an investigational new drug that is being evaluated by Astellas Pharma for the treatment of solid tumors.[1] It is an PROTACs degrader of the KRAS protein harboring a G12D mutation.[1][2][3]
Clinical trials
Setidegrasib in combination with either FOLFIRINOX or NALIRIFOX chemotherapy is currently in phase 3 clinical trials for the treatment of pancreatic cancer.[4]
References
- ↑ 1.0 1.1 "Setidegrasib - Astellas Pharma". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800068435.
- ↑ "Targeted protein degradation: bridging chemical biology and clinical translation". Acta Pharmacologica Sinica. July 2026. doi:10.1038/s41401-026-01861-2. PMID 42414544.
- ↑ "Discovery of KRAS(G12D) selective degrader ASP3082". Nature Communications Chemistry 8 (1). August 2025. doi:10.1038/s42004-025-01662-4. PMID 40849515. Bibcode: 2025CmChe...8..254Y.
- ↑ Clinical trial number NCT07409272 for "A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given with either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People with Pancreatic Cancer" at ClinicalTrials.gov
 |  |
